US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
93 deals · US$26bndisclosed · Healthcare · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| May 2026 | Mobia Medical | – | – | IPO | Announced | 150.0 | Medtech | Latham & Watkins (issuer)BofA Securities (lead manager)J.P. Morgan (lead manager)Goldman Sachs (lead manager)BTIG (lead manager)Nomura (lead manager)WR Securities (lead manager)Cleary Gottlieb Steen & Hamilton (lead manager) |
| May 2026 | Odyssey Therapeutics | – | – | IPO | Announced | 279.0 | Biotech+1 | Covington & Burling (issuer)J.P. Morgan (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Wedbush Securities (lead manager)Oppenheimer & Co. (lead manager)Cooley (lead manager) |
| May 2026 | Odyssey Therapeutics | – | – | Placement | Pending | 25.0 | Biotech+1 | J.P. Morgan (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Wedbush Securities (lead manager)Oppenheimer & Co. (lead manager)Cooley (lead manager) |
| May 2026 | Imricor Medical Systems | – | – | Placement | Completed | 42.7 | Medtech | Morgans (lead manager)Canaccord Genuity (lead manager)Taylor Collison (lead manager) |
| Apr 2026 | Hemab Therapeutics Holdings | – | – | IPO | Announced | 301.5 | Biotech+1 | WilmerHale (issuer)Goldman Sachs (lead manager)Jefferies (lead manager)Evercore (lead manager)Wedbush Securities (lead manager)Goodwin (lead manager) |
| Apr 2026 | Seaport Therapeutics | – | – | IPO | Announced | 254.9 | Biotech+1 | Goodwin (issuer)Goldman Sachs (lead manager)J.P. Morgan (lead manager)Leerink Partners (lead manager)Citi (lead manager)Stifel (lead manager)Latham & Watkins (lead manager) |
| Apr 2026 | Avalyn Pharma | – | – | IPO | Listed | 300.0 | Biotech+2 | Goodwin (issuer)Morgan Stanley (lead manager)Jefferies (lead manager)Evercore (lead manager)Guggenheim Securities (lead manager)Davis Polk (lead manager) |
| Apr 2026 | National Healthcare Properties | – | – | IPO | Listed | 462.0 | REITs+1 | Paul, Weiss (issuer)Venable (issuer)Greenberg Traurig (issuer)Wells Fargo Securities (lead manager)Morgan Stanley (lead manager)BMO Capital Markets (lead manager)Goldman Sachs (lead manager)RBC Capital Markets (lead manager)Sidley Austin (lead manager)Baird (lead manager) |
| Apr 2026 | Ionetix Corp. | – | – | Placement | Completed | 30.0 | Radiopharmaceuticals+1 | |
| Apr 2026 | Opus Genetics | – | – | Placement | Announced | 5.0 | Biotech+1 | Sidley Austin (issuer) |
| Apr 2026 | Arxis | – | – | IPO | Listed | 1,134.0 | Defence & Aerospace+2 | William Blair (lead manager)Davis Polk (issuer)Nomura (lead manager)WR Securities (lead manager)Ropes & Gray (lead manager)Goldman Sachs (lead manager)Morgan Stanley (lead manager)Jefferies (lead manager)Citi (lead manager)RBC Capital Markets (lead manager)Baird (lead manager)Guggenheim Securities (lead manager)Wells Fargo Securities (lead manager)Rothschild & Co (lead manager)Wolfe | Nomura Alliance (lead manager)Citizens JMP (lead manager) |
| Apr 2026 | Alamar Biosciences | – | – | IPO | Listed | 191.3 | Life Sciences+1 | Cooley (issuer)J.P. Morgan (lead manager)BofA Securities (lead manager)TD Securities (lead manager)Leerink Partners (lead manager)Stifel (lead manager)Latham & Watkins (lead manager) |
| Apr 2026 | Kailera Therapeutics | – | – | IPO | Announced | 625.0 | Biotech+1 | Latham & Watkins (issuer)William Blair (lead manager)J.P. Morgan (lead manager)Jefferies (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Evercore (lead manager)Paul Hastings (lead manager) |
| Apr 2026 | Obsidian Therapeutics | – | – | Placement | Completed | 350.0 | Biotech+2 | GoodwinSidley Austin (issuer)Leerink Partners (lead manager)TD Securities (lead manager)Piper Sandler (lead manager)William Blair (lead manager)LifeSci Capital (lead manager)Mintz (lead manager) |
| Apr 2026 | Korsana Biosciences | – | – | Placement | Announced | 380.0 | Biotech+1 | Cooley (lead manager) |
| Mar 2026 | Pulmatrix | – | – | Placement | Announced | 19.0 | Biotech | Palladium Capital Group (lead manager) |
| Mar 2026 | Janus Living | – | – | IPO | Listed | 840.0 | REITs+1 | Latham & Watkins (issuer)Ballard Spahr (issuer)BofA Securities (lead manager)J.P. Morgan (lead manager)Wells Fargo Securities (lead manager)Barclays (lead manager)Goldman Sachs (lead manager)RBC Capital Markets (lead manager)Morgan Stanley (lead manager)BNP Paribas (lead manager)Crédit Agricole CIB (lead manager)KeyBanc Capital Markets (lead manager)PNC Capital Markets (lead manager)Scotiabank (lead manager)TD Securities (lead manager)Truist Securities (lead manager)BTIG (lead manager)Capital One Securities (lead manager)Huntington Securities (lead manager)M&T Securities (lead manager)Raymond James (lead manager)Regions Securities (lead manager)Santander (lead manager)SMBC Nikko Securities (lead manager)Sidley Austin (lead manager) |
| Mar 2026 | Tenon Medical | – | – | Convertible | Completed | 4.3 | Medtech | Sichenzia Ross Ference Carmel (issuer)WallachBeth Capital (lead manager)Sheppard, Mullin, Richter & Hampton (lead manager) |
| Mar 2026 | MiniMed Group | – | – | IPO | Announced | 560.0 | Medtech | William Blair (lead manager)Cleary Gottlieb Steen & Hamilton (issuer)Goldman Sachs (lead manager)BofA Securities (lead manager)Citi (lead manager)Morgan Stanley (lead manager)Barclays (lead manager)Deutsche Bank (lead manager)Mizuho Securities (lead manager)Wells Fargo Securities (lead manager)Evercore (lead manager)Piper Sandler (lead manager)BTIG (lead manager)Davis Polk (lead manager) |
| Mar 2026 | Medline | Blackstone | – | Follow-on offering | Announced | 3,075.0 | Healthcare+2 | Simpson Thacher & Bartlett (issuer)Goldman Sachs (lead manager)Morgan Stanley (lead manager)BofA Securities (lead manager)J.P. Morgan (lead manager)Blackstone Securities Partners (lead manager)TCG Capital Markets (lead manager)Barclays (lead manager)Citi (lead manager)Deutsche Bank (lead manager)Jefferies (lead manager)UBS (lead manager)Evercore (lead manager)BMO Capital Markets (lead manager)BNP Paribas (lead manager)MUFG (lead manager)RBC Capital Markets (lead manager)Santander (lead manager)Societe Generale (lead manager)TD Securities (lead manager)Wells Fargo Securities (lead manager)Nomura (lead manager)WR Securities (lead manager)Leerink Partners (lead manager)Macquarie Capital (lead manager)Mizuho Securities (lead manager)Piper Sandler (lead manager)Truist Securities (lead manager)William Blair (lead manager)Baird (lead manager)Rothschild & Co (lead manager)Stifel (lead manager)BTIG (lead manager)ING (lead manager)IMI Intesa Sanpaolo (lead manager)NCMG (lead manager)Perella Weinberg Partners (lead manager)Academy Securities (lead manager)AmeriVet Securities (lead manager)Blaylock Van (lead manager)C.L. King & Associates (lead manager)Drexel Hamilton (lead manager)Loop Capital Markets (lead manager)Mischler Financial Group (lead manager)R. Seelaus & Co. (lead manager)Samuel A. Ramirez & Company (lead manager)Siebert Williams Shank & Co. (lead manager)Tigress Financial Partners (lead manager)Latham & Watkins (lead manager) |
| Mar 2026 | Candid Therapeutics | – | – | Placement | Pending | 505.0 | Biotech+1 | Cooley (issuer)Jefferies (lead manager)BofA Securities (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Latham & Watkins (lead manager) |
| Feb 2026 | Avalon GloboCare Corp. | – | – | Placement | Completed | 3.3 | Healthcare+2 | Roth Capital Partners (issuer)H.C. Wainwright & Co. (lead manager) |
| Feb 2026 | Generate Biomedicines | – | – | IPO | Listed | 400.0 | Biotech+2 | Goodwin (issuer)Goldman Sachs (lead manager)Morgan Stanley (lead manager)Piper Sandler (lead manager)Guggenheim Securities (lead manager)Cantor Fitzgerald (lead manager)Latham & Watkins (lead manager) |
| Feb 2026 | Sensei Biotherapeutics | – | – | Placement | Pending | 200.0 | Biotech+2 | Cantor Fitzgerald (issuer)Citi (issuer)Sidley Austin (issuer)Leerink Partners (lead manager) |
| Feb 2026 | Liminatus Pharma | – | – | Follow-on offering | Announced | 4.0 | Biotech+2 | Loeb & Loeb (issuer)Maxim Group (lead manager)Lucosky Brookman (lead manager) |
| Feb 2026 | Agomab Therapeutics NV | – | – | IPO | Announced | 200.0 | Biotech+2 | Goodwin (issuer)Baker McKenzie (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)Leerink Partners (lead manager)Van Lanschot Kempen (lead manager)Davis Polk (lead manager)Clifford Chance (lead manager) |
| Feb 2026 | SpyGlass Pharma | – | – | IPO | Announced | 150.0 | Ophthalmology+1 | Jefferies (lead manager)Leerink Partners (lead manager)Citi (lead manager)Stifel (lead manager)Latham & Watkins (lead manager) |
| Feb 2026 | Eikon Therapeutics | – | – | IPO | Announced | 381.2 | Oncology+1 | Covington & Burling (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)BofA Securities (lead manager)Cantor Fitzgerald (lead manager)Mizuho Securities (lead manager)Davis Polk (lead manager) |
| Feb 2026 | Veradermics | – | – | IPO | Announced | 256.3 | Dermatology+2 | Ropes & Gray (issuer)Jefferies (lead manager)Leerink Partners (lead manager)Citi (lead manager)Cantor Fitzgerald (lead manager)Cooley (lead manager) |
| Feb 2026 | Perspective Therapeutics | – | – | Follow-on offering | Announced | 175.0 | Radiopharmaceuticals+2 | Piper Sandler (lead manager)UBS (lead manager)Oppenheimer & Co. (lead manager)Truist Securities (lead manager)LifeSci Capital (lead manager) |
| Jan 2026 | INVO Fertility | – | – | Registered direct or warrant-inducement placement | Pending | 7.5 | Healthcare Services | Maxim Group |
| Jan 2026 | Polaryx Therapeutics | – | – | Direct listing | Completed | – | Biotech+1 | Maxim Group (issuer)Gibson Dunn (issuer)Brownstein Hyatt Farber Schreck (issuer) |
| Jan 2026 | Ekso Bionics Holdings | – | – | Placement | Pending | 5.3 | Medtech | Lake Street Capital Markets (lead manager) |
| Jan 2026 | Aktis Oncology | – | – | IPO | Listed | 317.7 | Biotech+2 | Paul Hastings (issuer)Goodwin (issuer)J.P. Morgan (lead manager)BofA Securities (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Davis Polk (lead manager) |
| Dec 2025 | Freenome | – | – | Placement | Completed | 240.0 | Diagnostics+2 | Goodwin (issuer)Jefferies (lead manager)Leerink Partners (lead manager)White & Case (lead manager) |
| Dec 2025 | Saluda Medical | – | – | IPO | Listed | 154.2 | Medtech | TPG Capital BD (issuer)Latham & Watkins (issuer)Johnson Winter Slattery (issuer)Barnes & Thornburg (issuer)Grant Thornton (issuer)Bell Potter (lead manager)Morgans (lead manager)E&P Capital (lead manager)CommSec (lead manager) |
| Dec 2025 | Apimeds Pharmaceuticals US | – | – | Convertible | Completed | 10.9 | Pharma+1 | Nelson Mullins Riley & Scarborough (issuer)EF Hutton (lead manager) |
| Aug 2025 | AVITA Medical | – | – | Placement | Completed | 15.0 | Medtech | MST Financial (lead manager) |
| May 2025 | EBR Systems | – | – | Placement | Completed | 39.8 | Medtech | Johnson Winter Slattery (issuer) |
| Mar 2025 | Imricor Medical Systems | – | – | Placement | Completed | 44.2 | Medtech | Morgans (lead manager) |
| – | Lakewood-Amedex Biotherapeutics | – | – | Direct listing | Announced | – | Biotech+1 | RBW Capital Partners (issuer) |
| – | Silexion Therapeutics Corp | – | – | Follow-on offering | Announced | 2.5 | Biotech+2 | Conyers (issuer)Greenberg Traurig (issuer)H.C. Wainwright & Co. (lead manager)Ellenoff Grossman & Schole (lead manager) |
| – | Vogenx | – | – | IPO | Announced | 81.3 | Biotech | Smith Anderson (issuer)JonesTrading (lead manager)Sichenzia Ross Ference Carmel (lead manager) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built